- Home
- CARV vs PCSA Comparison
CARV vs PCSA Comparison
Compare CARV & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARV
- PCSA
- Stock Information
- Founded
- CARV 1948
- PCSA 2011
- Country
- CARV United States
- PCSA United States
- Employees
- CARV N/A
- PCSA N/A
- Industry
- CARV Savings Institutions
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- CARV Finance
- PCSA Health Care
- Exchange
- CARV Nasdaq
- PCSA Nasdaq
- Market Cap
- CARV 13.2M
- PCSA 12.0M
- IPO Year
- CARV 1994
- PCSA N/A
- Fundamental
- Price
- CARV N/A
- PCSA $0.48
- Analyst Decision
- CARV
- PCSA Strong Buy
- Analyst Count
- CARV 0
- PCSA 1
- Target Price
- CARV N/A
- PCSA $1.00
- AVG Volume (30 Days)
- CARV 27.8K
- PCSA 21.2M
- Earning Date
- CARV 11-13-2025
- PCSA 10-29-2025
- Dividend Yield
- CARV N/A
- PCSA N/A
- EPS Growth
- CARV N/A
- PCSA N/A
- EPS
- CARV N/A
- PCSA N/A
- Revenue
- CARV $22,032,000.00
- PCSA N/A
- Revenue This Year
- CARV N/A
- PCSA N/A
- Revenue Next Year
- CARV N/A
- PCSA N/A
- P/E Ratio
- CARV N/A
- PCSA N/A
- Revenue Growth
- CARV N/A
- PCSA N/A
- 52 Week Low
- CARV $1.30
- PCSA $0.15
- 52 Week High
- CARV $3.85
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- CARV 61.85
- PCSA 86.63
- Support Level
- CARV $2.40
- PCSA $0.19
- Resistance Level
- CARV $2.83
- PCSA $0.21
- Average True Range (ATR)
- CARV 0.15
- PCSA 0.04
- MACD
- CARV 0.02
- PCSA 0.03
- Stochastic Oscillator
- CARV 80.83
- PCSA 78.50
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).